IDEAS home Printed from https://ideas.repec.org/a/oup/scippl/v49y2022i1p127-131..html
   My bibliography  Save this article

Restoring the antibiotic R&D market to combat the resistance crisis
[21 U.S. Code § 360bb—Designation of Drugs for Rare Diseases or Conditions]

Author

Listed:
  • Lucas Böttcher
  • Hans Gersbach
  • Didier Wernli

Abstract

Antibiotic resistance has developed into a major public health concern due to the widespread prevalence of bacterial infections such as sepsis and urethritis and the frequent occurrence of opportunistic infections in immunocompromised patients. Unfortunately, the pipeline for new antibiotics has been almost stagnant for more than three decades. The main reason is that the antibiotics R&D market is dysfunctional since antibiotics R&D is a very risky business model that is not profitable and attractive for investors under current market and policy conditions. Our work analyzes the main economic and policy challenges in antibiotics R&D and highlights the need of rapid action in developing new push and pull incentives for antibiotics R&D. We suggest three core elements of a redesign of the R&D market: (1) levying a fee on the nonhuman use of antibiotics, (2) using these revenues to pay for market entry rewards, and (3) rewarding companies for the development of new antibiotics that are effective against resistant bacteria (‘the resistance premium’).

Suggested Citation

  • Lucas Böttcher & Hans Gersbach & Didier Wernli, 2022. "Restoring the antibiotic R&D market to combat the resistance crisis [21 U.S. Code § 360bb—Designation of Drugs for Rare Diseases or Conditions]," Science and Public Policy, Oxford University Press, vol. 49(1), pages 127-131.
    • Handle: RePEc:oup:scippl:v:49:y:2022:i:1:p:127-131.
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1093/scipol/scab067
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oup:scippl:v:49:y:2022:i:1:p:127-131.. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Oxford University Press (email available below). General contact details of provider: https://academic.oup.com/spp .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.